Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 million in its upsized ...

Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 million in its upsized ...

Studies published in Nature Cancer reveal how bacterial presence in head and neck cancers affects treatment response, ...

Irene Blair was expected to have another six to eight months to live in June, after her pancreatic cancer rapidly advanced to ...

Padcev is approved for use in combination with the programmed death 1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment and ...

For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...

Histological analysis of the resected specimen diagnosed a Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) with mild lymphocytic submucosal inflammation. Crucially, there was no ...

CystoSmart™, an AI software tool for bladder tumor detection in patients undergoing screening and surveillance endoscopic examination of the bladder is brand agnostic and compatible with flexible and ...

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being over age 55. And the unfortunate reality is that women are often diagnosed at ...

A redesigned immune-activating cancer drug has produced striking early results in a small clinical trial, shrinking tumors ...

Gene Holdings Inc. rises on 62% CR rate in Phase 2 NMIBC trial. Click to learn about ENGN and its gene delivery tech, market ...